The regulatory landscape for actively personalized cancer immunotherapies

Cedrik M. Britten, Harpreet Singh-Jasuja, Bruno Flamion, Axel Hoos, Christoph Huber, Karl Josef Kallen, Samir N. Khleif, Sebastian Kreiter, Michaela Nielsen, Hans Georg Rammensee, Ugur Sahin, Thomas Hinz, Ulrich Kalinke

Research output: Contribution to journalLetter

33 Scopus citations
Original languageEnglish (US)
Pages (from-to)880-882
Number of pages3
JournalNature Biotechnology
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2013

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Molecular Medicine
  • Biomedical Engineering

Cite this

Britten, C. M., Singh-Jasuja, H., Flamion, B., Hoos, A., Huber, C., Kallen, K. J., Khleif, S. N., Kreiter, S., Nielsen, M., Rammensee, H. G., Sahin, U., Hinz, T., & Kalinke, U. (2013). The regulatory landscape for actively personalized cancer immunotherapies. Nature Biotechnology, 31(10), 880-882. https://doi.org/10.1038/nbt.2708